Barreto-Rodríguez JO, Mejía ME, Buendía-Roldán I

Language: Spanish
References: 9
Page: 256-261
PDF size: 284.89 Kb.

ABSTRACT

IPF is a disease characterized by progressive and irreversible pulmonary fibrosis of unknown etiology, incidence and prevalence in the world is highly variable; in Mexico we have no representative epidemiological data. An inquiry was conducted of 419 pulmonologists, of which 168 responded pulmonologists around the country. On average each pulmonologist diagnosed 8 patients with IPF annually. Reference centers that recognize are INER 27%, 6% CMN IMSS, HGM 2%, 2% CEPREP, and 63% denied having reference center. For the diagnostic approach 89% has HRCT and 11% do not have it, 37% is support of an expert radiologist, 31% of an expert pathologist and 63% do not have these specialists. Regarding the initial treatment prescribed prednisone 85%, 46% n-acetilcisteine, 39% azatioprine. Colchicine 12% and 8% pirfenidone. With the results of this study we can conclude that Mexico needs not only train experts pulmonologists in interstitial diseases, it is also essential to increase the number of radiologists and expert pathologists in the subject and form an adequate network of national reference for obtain reliable epidemiological data.

REFERENCES

1. Raghu G, Collard HR, Egan JJ, et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183(6):788-824. doi: 10.1164/rccm.2009-040GL.

2. Selman M, King TE, Pardo A; American Thoracic Society; European Respiratory Society; American College of Chest Physicians. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134(2):136-151.

3. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol 2013;5:483-492. doi: 10.2147/CLEP.S54815.

4. Richeldi L, du Bois RM, Raghu G, et al; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370(22):2071-2082. doi: 10.1056/NEJMoa1402584.

5. King TE Jr, Bradford WZ, Castro-Bernardini S, et al; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370(22):2083-2092. doi: 10.1056/NEJMoa1402582.

6. Collard HR, Moore BB, Flaherty KR, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176(7):636-643.

7. Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Rev 2014;23(132): 225-230. doi: 10.1183/09059180.00001914.

8. Curbelo P. Encuesta de EPID en Latinoamérica-ALAT 2013. Respirar 2013;5 (2):5-8.

9. National Heart, Lung and Blood Institute. Commonly used three-drug regime for idiopathic pulmonary fibrosis found harmful. Date last accessed: November 2, 2011. Date last updated: October 21, 2011. Available from: www.nih-gov/news/health/oct2011/nhlbi-21.htm.